Kaletra Oral Solution and Nerlynx

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer information for this interaction is not currently available.GENERALLY AVOID: Coadministration with potent inhibitors of CYP450 3A4 such as ritonavir may significantly increase the plasma concentrations and risk of toxicity of of neratinib, which is primarily metabolized by the isoenzyme. In a study with 24 healthy volunteers, administration of a single 240 mg oral dose of neratinib with the potent CYP450 3A4 inhibitor ketoconazole (400 mg once daily for 5 days) increased neratinib peak plasma concentration (Cmax) and systemic exposure (AUC) by 3.2- and 4.8-fold, respectively, compared to administration of neratinib alone. Ketoconazole also reduced the mean apparent oral clearance of neratinib by 75% and increased its mean elimination half-life by approximately 6 hours. MANAGEMENT: Given the potential for increased risk of toxicity, concomitant use of neratinib with potent inhibitors of CYP450 3A4 such as ritonavir should generally be avoided. According to some authorities, if the CYP450 3A4 inhibitor cannot be avoided, the dose of neratinib should be reduced to 40 mg once daily with a strong CYP450 3A4 inhibitor and 200 mg once daily with a moderate CYP450 3A4 inhibitor. The previous dose of neratinib may be resumed following discontinuation of a strong or moderate CYP450 3A4 inhibitor. References "Product Information. Nerlynx (neratinib)." Puma Biotechnology, Inc., Los Angeles, CA. "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0 Cerner Multum, Inc. "Australian Product Information." O 0 View all 4 references

GENERALLY AVOID: Coadministration with potent inhibitors of CYP450 3A4 such as ritonavir may significantly increase the plasma concentrations and risk of toxicity of of neratinib, which is primarily metabolized by the isoenzyme. In a study with 24 healthy volunteers, administration of a single 240 mg oral dose of neratinib with the potent CYP450 3A4 inhibitor ketoconazole (400 mg once daily for 5 days) increased neratinib peak plasma concentration (Cmax) and systemic exposure (AUC) by 3.2- and 4.8-fold, respectively, compared to administration of neratinib alone. Ketoconazole also reduced the mean apparent oral clearance of neratinib by 75% and increased its mean elimination half-life by approximately 6 hours.

MANAGEMENT: Given the potential for increased risk of toxicity, concomitant use of neratinib with potent inhibitors of CYP450 3A4 such as ritonavir should generally be avoided. According to some authorities, if the CYP450 3A4 inhibitor cannot be avoided, the dose of neratinib should be reduced to 40 mg once daily with a strong CYP450 3A4 inhibitor and 200 mg once daily with a moderate CYP450 3A4 inhibitor. The previous dose of neratinib may be resumed following discontinuation of a strong or moderate CYP450 3A4 inhibitor.

Kaletra Oral Solution

Generic Name: lopinavir / ritonavir

Brand name: Kaletra

Synonyms: Kaletra

What is Kaletra Oral Solution?

Nerlynx

Generic Name: neratinib

Brand name: Nerlynx

Synonyms: n.a.

What is Nerlynx?